

# Ann Gils

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3002156/publications.pdf>

Version: 2024-02-01

37  
papers

2,443  
citations

279798

23  
h-index

330143

37  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1973  
citing authors

#	ARTICLE	IF	CITATIONS
1	Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy. <i>Journal of Pediatrics</i> , 2022, 240, 150-157.e4.	1.8	10
2	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 106-118.	2.4	18
3	Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 390-397.	1.5	11
4	Anti-infliximab antibodies: How to compare old and new data?. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 177, 112842.	2.8	10
5	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 637-646.e11.	4.4	67
6	Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 189, 113433.	2.8	2
7	Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 945-954.	4.7	10
8	Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 864-872.	1.3	83
9	Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2232-2235.e1.	0.7	11
10	Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1248-1256.	1.3	32
11	P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S409-S410.	1.3	1
12	Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 459-466.	2.0	12
13	Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 478-485.	1.6	25
14	Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 847-853.	1.8	36
15	Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. <i>AAPS Journal</i> , 2019, 21, 10.	4.4	13
16	Optimising infliximab induction dosing for patients with ulcerative colitis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 782-795.	2.4	27
17	Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1343-1351.e1.	1.3	240
18	Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 346-355.	3.7	41

#	ARTICLE	IF	CITATIONS
19	P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S439-S439.	1.3	9
20	Letter: overcoming secondary loss of response to infliximab – it is not the drug, it is how you use it! Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1029-1030.	3.7	1
21	Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1316-1325.	1.3	47
22	Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1937-1946.e8.	4.4	113
23	Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor. <i>Analytical Chemistry</i> , 2017, 89, 3664-3671.	6.5	65
24	Current Practice of Therapeutic Drug Monitoring of Biopharmaceuticals in Psoriasis Patients. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 356-359.	2.0	13
25	Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 344-349.	2.0	18
26	Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1510-1515.	1.9	62
27	Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 53-59.	1.3	57
28	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 101-111.	1.2	27
29	Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e206.	2.5	52
30	Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 125, 62-67.	2.8	29
31	Variability in Golimumab Exposure: A Real-Life Observational Study in Active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 575-581.	1.3	71
32	Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 543-549.	4.4	154
33	Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 479-485.	2.0	37
34	An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2172-2177.	1.9	35
35	Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, 1320-1329.e3.	1.3	745
36	Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S39-50.	2.0	77

#	ARTICLE	IF	CITATIONS
37	Detection of infliximab levels and anti- $\alpha$ -infliximab antibodies: a comparison of three different assays. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 765-771.	3.7	182